• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Should Raised Earnings Outlook Require Action From Philip Morris International Stock Investors?

    Simply Wall St·09/11/2026 13:21:12
    Listen to the news
    • Philip Morris International raised its 2026 reported diluted EPS guidance to a range of US$7.28 to US$7.43, citing currency effects, while highlighting progress in smoke free products such as IQOS and ZYN.
    • Expanded ZYN nicotine pouch offerings, fresh FDA marketing authorizations and a new Colorado production facility signal a deeper commitment to higher margin, smoke free revenue streams.
    • The next step is to examine how Philip Morris International's investment narrative could shift as ZYN gains scale within the wider smoke free mix.
    Spot 6 dividend fortresses built around recurring income streams, then compare Philip Morris International's higher margin smoke free pivot with peers that also lean on steady cash returns.

    Philip Morris International Investment Narrative Recap

    To own Philip Morris International, you need to be comfortable with a tobacco group leaning harder into smoke free nicotine while combustibles structurally shrink. The raised 2026 EPS guidance tied to currency does not change that core belief. It does show that forex is still a meaningful swing factor on reported earnings in the near term.

    The main short term catalyst remains execution in IQOS and ZYN, particularly in the US, where new formats and capacity are being built out. The biggest risk is that growth in smoke free products slows or faces regulatory pushback before it can fully offset ongoing declines in traditional cigarettes.

    The most relevant recent announcement for this story is management’s commentary around ZYN demand and the new Colorado manufacturing center. The CEO highlighted that earlier inventory issues have been addressed and that the Colorado facility should support higher output and a broader pouch portfolio, including larger cans and new strength options.

    For investors, that goes straight to the core thesis and risk. If ZYN can scale cleanly with enough supply, appropriate pricing and FDA cleared SKUs, it supports the margin mix shift away from combustibles. Any production hiccups, regulatory setbacks or weaker than expected category growth would affect that same catalyst in the opposite direction.

    Philip Morris International's current earnings are reported at US$10.8b, with analyst consensus pointing to US$15.5b of earnings and US$49.8b of revenue by 2029. This outlook implies revenue growth of 5.4% per year and an earnings increase of about US$4.7b by the 2029 forecast year.

    Uncover why Philip Morris International's fair value indicates a 7% potential upside to its current price, which could narrow quickly.

    NYSE:PM 1-Year Stock Price Chart
    NYSE:PM 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate view focuses squarely on regulatory pushback. The most cautious analysts, who were working with about US$48.9b of 2029 revenue and US$15.0b of earnings, see tougher rules on IQOS and ZYN as a bigger threat to Philip Morris International than consensus implies. These expectations were set before the latest guidance and ZYN updates, so you may want to compare both narratives and decide which feels closer to your own view.

    Explore 5 other Philip Morris International fair value estimates, including one that suggests as much as 8% downside from the current price.

    Decide For Yourself

    Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

    Looking For More Ideas Beyond Philip Morris International?

    Once you have a view on Philip Morris International, it can help to widen the lens and compare it with other businesses that match your income, quality, or value priorities. The Simply Wall St Screener lets you filter for those traits directly so you are not relying on headlines or hunches.

    • If stable cash generation and lower volatility appeal to you, start by reviewing 11 resilient stocks with low risk scores, which already screen well on resilience and balance sheet strength.
    • For investors who care most about quality at a reasonable price, there is a focused set of 33 high quality undervalued stocks that pair solid fundamentals with more modest expectations baked into the share price.
    • If you want ideas that are not already crowded, consider a group of 18 high quality undiscovered gems where underlying financials look robust but market attention still feels limited.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.